Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDF
CRDF | US
1.59
USD0.01
0.63%
CRDF | US
Loading StockChartView...
About CRDF
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
1.59
Open
1.58
High
1.63
Low
1.56
Cardiff Oncology Inc. a clinical-stage biotechnology company develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene Inc. and changed its name to Cardiff Oncology Inc. in May 2012. Cardiff Oncology Inc. was incorporated in 1999 and is headquartered in San Diego California.
View LessCRDF | US
Risk
56.8
Sharpe
-0.52
Luna's Score
51/100
Recommendation
Hold
Luna says (CRDF | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
54.0%1 month
56.8%3 months
100.2%6 months
85.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.48
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
-3.66
Ent. to rev.
107.36
PEG
-
Other Fundamentals
EBITDA
-44.21M
MarketCap
74.01M
MarketCap(USD)
74.01M
Div. yield
-
Op. margin
-7.70K
Erngs. growth
-
Rev. growth
50.90
Ret. on equity
-58.80
Short ratio
14.11
Short perc.
15.08
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.17
Range1M
0.43
Range3M
1.60
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.36
Price X volume
1.41M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.66 | 0.53 | Cheaper |
| Ent. to Revenue | 107.36 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.48 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.17 | 72.80 | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 74.01M | 3.66B | Emerging |
